Resources

In this blog, Linda Bedenik, our Head of Biosolutions and International Policy, and Maddie Cass, our Policy and Public Affairs Manager, reflect on the tireless work they have done, and will continue to do, to propel innovative biosolutions in the UK nationally and across Europe.

ARC West London and Imperial College London’s Imperial Incubator have announced the two winning startups of the Leap Lab Pass.

In this blog, Jaime Eaton, reflects on this month's Community Connects series, bringing together diverse expertise to tackle the most pressing challenges in our sector.

Complement Therapeutics (CTx, has dosed the first patient in Opti-GAIN.

In this blog, Kate Barclay, Skills Strategy Consultant at BIA, shares the impact BIA member evidence has on the UK’s Skilled Worker Visa.

RxCelerate launched RxPlorer™: a new technology for finding small molecule hits, particularly against challenging, previously undruggable targets.

There are a number of significant moving pieces right now in the sector, including the major strategic shift at UKRI and Innovate launched last Thursday.

Abselion has appointed Dale Gordon as Chair of the Board of Directors.

BIA BioSolutions is here: a new strategic platform dedicated to championing the UK’s engineering biology ecosystem beyond health. Discover how we are bridging the gap between world-class science and industrial scale to drive global sustainability.

Salvivo has been awarded £99,080 in Innovate UK Analysis for Innovators funding to enable evaluation of its FishburneTabs™ platform for biomarker detection with the National Physical Laboratory (NPL).

New parliamentary scrutiny of the UK’s innovation landscape has reinforced longstanding concerns about how investment in innovation is distributed across the country, with Pioneer Group, a specialist in technology infrastructure and venture building, urging swift action to address persistent barriers to research commercialisation.

Sonjoy Brahma, tranScrip’s VP of Clinical Operations, joins Joab Williamson of Faron Pharmaceuticals to unpack the operational realities of life in a small emerging biotech. They’ll explore the pressures of rare oncology development, how cash runway and clinical milestones shape decision-making and why flexibility, external expertise and careful planning are essential to moving programmes forward with confidence.

Researchers have discovered a drug target that could potentially help tackle drug-resistant tuberculosis, one of the biggest causes of death worldwide.

The Modelling-Informed Medicine Centre (MiMeC) will provide a new UK hub for research in the emerging modelling-informed medicine field.

The launch of the NIHR Industry hub last week, the launch of UKRI/Innovate strategy this Thursday and a landmark Mansion House event tomorrow all signal forward momentum on Industrial Strategy.

In this guest blog, Valerie Pinkerton, UK TNFD & Transition Plans Lead at the Green Finance Institute, explores why nature-related risks are becoming increasingly important for the pharmaceutical and biotechnology sector.

BIA member Asma Aslam, Senior Corporate Tax Manager at Frazier & Deeter, explores how a period of tighter capital and greater scrutiny has reshaped expectations around execution, value creation and operational discipline.

PIR International recently partnered with Gilgamesh Pharmaceuticals in appointing Bridget Walton as VP Regulatory Affairs.

The BioIndustry Association (BIA) is pleased to announce the appointment of Will James, partner at Osborne Clarke LLP, as Vice-Chair of its Intellectual Property Advisory Committee (IPAC).

Nominations were declared open today for the Life Sciences Week Awards - the climax of a national programme of health tech events launched in Birmingham, UK.